8月25日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者 参考。 2025.08. 25 东风科技：东风投资将成为公司间接股东 【品大事】 汇顶科技：公司总裁柳玉平因涉嫌内幕交易被证监会立案 汇顶科技公告，公司总裁柳玉平于2025年8月22日收到中国证券监督管理委员会下发的《立案告知 书》，因涉嫌内幕交易，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法 规，中国证监会决定对柳玉平进行立案。本次立案系针对柳玉平个人，与公司日常经营管理和业务活 动无关，不会对公司及子公司生产经营活动产生影响。 东风科技公告，8月22日，间接股东东风汽车集团股份有限公司与东风汽车集团(武汉)投资有限公司 （简称"东风投资"）签署了《东风汽车集团(武汉)投资有限公司与东风汽车集团股份有限公司之吸收 合并协议》，东风投资拟吸收合并东风集团股份。本次间接股东吸收合并完成后，东风投资将成为公 司间接股东。本次间接股东吸收合并不会导致公司控股股东、实际控制人发生变化，不会对公司正常 生产经营活动构成重大影响。 华依科技：筹划发行H股股票并在香港联交所上市 华依科技公告，公司为满足国际化战略 ...

Group 1 - The core viewpoint of the article highlights that Maike Bio (300463.SZ) is leveraging AI technology to innovate in the medical field, particularly through its "Smart Laboratory" platform [2] - The company has achieved full-process automation in blood collection management, sample processing, and result interpretation, creating a closed-loop system of "smart testing - smart management - smart operation" [2] - Maike Bio is currently applying AI and big data models to various projects, including urine, blood cell, and pathology tests, and is exploring broader applications of AI in the medical sector [2]

证券日报网讯 8月25日晚间，宝莱特发布公告称，公司已完成工商变更登记，注册资本增至26，457.59 万元，经营范围新增技术服务、技术开发等项目。变更后公司名称为广东宝莱特医用科技股份有限公 司，法定代表人为燕金元，住所位于珠海市高新区科技创新海岸创新一路2号。 （文章来源：证券日报） ...

Group 1 - The stock of Zhongjin Medical (ZJYL) opened up by 10.51% on August 25, reaching $0.8 per share, with a total transaction volume of $47,700 and a market capitalization of $125 million [1] - As of March 31, 2025, Zhongjin Medical reported total revenue of $9.8815 million, a year-on-year decrease of 6.4%, and a net profit attributable to the parent company of -$89,000, representing a year-on-year decrease of 104.96% [1] - Zhongjin Medical Equipment International Co., Ltd. is a Cayman Islands-registered holding company that primarily operates through its domestic subsidiary, Changzhou Zhongjin Medical Equipment Co., Ltd., which was established in January 2006 and has been recognized as a national high-tech enterprise since 2012 [1] Group 2 - The company specializes in the research and manufacturing of high-end rehabilitation equipment, having developed into a top-tier global manufacturer over more than a decade [1] - Its product range includes walking aids, respiratory medical devices, smart nano bathing equipment, and fitness equipment specifically designed for the elderly and special populations, as well as disaster relief products [1]

Core Insights - Shenzhen Yahui Long Biotechnology Co., Ltd. reported its 2025 semi-annual performance, achieving operating revenue of 808 million yuan and a net profit attributable to shareholders of 26.27 million yuan [1] - The company has made significant advancements in research and development, with an investment of 143 million yuan and the approval of 14 new domestic registration certificates for chemiluminescent detection reagents [1] - The company has expanded its overseas market presence, installing 544 chemiluminescent instruments, with a notable increase in reagent sales revenue by 60.82% year-on-year [1] Financial Performance - Operating revenue for the first half of 2025 reached 808 million yuan [1] - Net profit attributable to shareholders was 26.27 million yuan, while the net profit excluding non-recurring items was 50.03 million yuan [1] - Total assets amounted to 4.299 billion yuan, and net assets were 2.668 billion yuan [1] Research and Development - The company invested 143 million yuan in R&D during the first half of 2025 [1] - A total of 14 new chemiluminescent detection reagent registration certificates were approved, enhancing the product lineup [1] - The company has 184 chemiluminescent diagnostic projects with domestic and international registration certificates, including 62 projects in autoimmune diagnostics [1] Market Expansion - The company installed 544 chemiluminescent instruments, including 47 units of the 300-speed model [1] - The overseas business covers 120 countries and regions across the Americas, Europe, Asia, and Africa [1] - Reagent sales revenue increased by 60.82% year-on-year, indicating strong market demand [1] Smart Manufacturing - The company has advanced its "smart manufacturing" initiatives, completing the smart upgrade of two production lines for reagent manufacturing [2] - The MES system is being steadily implemented, enhancing the digitalization level of production lines and improving production efficiency [2]

2025年上半年，公司取得稳健业绩表现。达成案例数攀升、医学设计中心和隐形矫治器生产基地的高效 运营，共同推动收入、毛利及经营利润同比增长。公司报告期间的盈利表现也得益于为应对预期更加严 峻的关税环境而採取的严格的费用控制措施，包括：暂缓若干区域销售、营销、临床支持及客户服务等 方面的人员招募，以及延迟中国内地以外医学设计中心及生产基地的运营。报告期间，中国内地以外全 球市场案例数(其中包括AngelAligner品牌矫治器，Aditek品牌矫治器，以及为重要战略客户简单病例定 制的矫治器)增长迅速，这反映集团进入新市场并从低垂果实中获益所取得的初步成功。 时代天使(06699)公布2025年中期业绩，收入为1.614亿美元，同比增加33.1%。 毛利为约1亿美元，同比 增加32.9%。经调整净利润为1950万美元，同比增加84.8%。公司拥有人应占利润1464.3万美元，同比增 长362.65%;每股盈利0.09美元，特别中期股息每股股份0.46港元。 公司凭藉高质量的医学设计支持、稳定的交付，结合由关键意见领袖(KOLs) 主导的持续性教育培训以 及为重要战略客户简单病例定制的矫治器等方式，扩大在中国内地 ...

人民财讯8月25日电，三友医疗(688085)8月25日晚间披露2025年半年报，上半年实现营业收入2.5亿元， 同比增长17.77%；归母净利润3660.08万元，同比增长2083.64%；基本每股收益0.11元。 ...

Core Viewpoint - Bluefan Medical (002382) shows a mixed performance in stock price and fund flow, with a slight increase in stock price but significant net outflows from major funds [1][2]. Fund Flow Summary - On August 25, 2025, Bluefan Medical's stock closed at 6.52 CNY, up 1.4%, with a turnover rate of 3.14% and a trading volume of 314,300 hands, resulting in a transaction amount of 204 million CNY [1]. - The fund flow data indicates a net outflow of 10.38 million CNY from major funds, accounting for 5.09% of the total transaction amount, while retail funds saw a net inflow of 14.35 million CNY, representing 7.04% of the total [1][2]. - Over the past five days, the stock experienced fluctuations in fund flows, with notable net inflows and outflows from different investor categories [2]. Company Performance Metrics - As of the latest report, Bluefan Medical has a total market value of 6.566 billion CNY, with a net asset value of 10.102 billion CNY, and a net profit of 77.0223 million CNY [3]. - The company’s price-to-earnings ratio (P/E) stands at 21.31, significantly lower than the industry average of 75.1, while the price-to-book ratio (P/B) is 0.81, compared to the industry average of 4.05 [3]. - The gross margin is reported at 17.17%, which is considerably lower than the industry average of 51.32%, and the net profit margin is 5.58%, below the industry average of 10.74% [3]. - In the first quarter of 2025, Bluefan Medical reported a main business revenue of 1.478 billion CNY, a year-on-year increase of 1.59%, and a net profit attributable to shareholders of 77.0223 million CNY, a significant year-on-year increase of 177.86% [3].

该公司主营业务为医疗工程建设和医疗器械产销，涉及医院整体建设、医疗设备供应等业务领域。最新 财报显示，2025年上半年公司营业收入5.28亿元，同比下降16.4%；归母净利润亏损776万元，同比下滑 155.3%。其中医疗服务收入大幅下降67.57%，医疗产品销售收入下降3.56%。 尚荣医疗股价报4.59元，较前一交易日下跌0.86%。盘中最高触及4.66元，最低下探至4.56元，成交量为 52.39万手，成交金额达2.41亿元。 风险提示：以上内容仅供参考，不构成任何投资建议。市场有风险，投资需谨慎。 来源：金融界 从资金流向来看，当日主力资金净流出3216.13万元，近五日累计净流出1.23亿元。公司当前总市值 38.81亿元，市盈率为负值。 ...

Core Viewpoint - The company, Opcon Vision, announced a cautious approach towards expanding its optical service terminals due to the current weakness in high-end consumer healthcare, focusing instead on sustainable growth potential in existing larger-scale optical service institutions [1] Group 1: Company Expansion Plans - By the first half of 2025, the company plans to increase its controlled optical terminals by 30, bringing the total to over 520 [1] - The company will also add 2 hospitals, resulting in a total of approximately 30 hospitals [1] Group 2: Investment Strategy - The company is shifting its investment focus from small optical service terminals to larger optical service institutions that already have significant business scale and sustainable growth potential [1] - The controlled subsidiaries are adopting a similarly cautious stance regarding new optical terminal establishments, emphasizing the need for substantial feasibility before implementation [1]